$DECN       
https://www.otcmarkets.com/stock/DECN/profile

                                                          

On December 18, 2020, the SEC and US Dept of Justice, announced actions against DECN due to alledged false claims about the supposed Covid-19 test being developed.

https://www.sec.gov/litigation/complaints/2020/comp-pr2020-327.pdf

On April 23, 2020, the SEC announced an action against DECN, suspending trading in the company's stock for two weeks.  There is currently a SEC court case ongoing where the SEC has identified the many reasons for the suspension.

https://www.otcmarkets.com/stock/DECN/news/SEC-Suspension-of-Trading?id=260085


Motion for Alternative Victim Notification Granted!

MINUTE ORDER granting the Government's 88 Motion for Victim Rights. The Government may provide notice to potential crime victims in this case through publication on a website maintained by the Department of Justice as an alternative to providing individualized notice. SO ORDERED. Signed by Judge Trevor N. McFadden on 3/17/2022.

ALTERNATIVE VICTIM NOTIFICATION PROCEDURES

The United States, through undersigned counsel, respectfully moves for authorization to use alternative victim notification procedures— namely, publication on a Department of Justice website—because the large number of potential crime victims in this case makes it impracticable to notify them on an individualized basis.

The website would provide a summary of the case, information regarding the case’s status, and other significant case-related documents, such as the charging documents. The website also would contain an e-mail address
and telephone number for a Victim Assistance Line through which individual potential crime victims could contact the Department of Justice with questions regarding the case.

https://www.justice.gov/criminal-vns/case/decision-diagnostics


 

DECN Earnings History

2021 Q1-Q3 - $1,374,707
  2020 - $29,668,622-
2019 - $3,132,295-
2018 - $2,240,220-
2017 - $2,991,404-
2016 - $2,967,357-
2015 - $2,771,345-
2014 - $1,841,010-

Total - $46,986,960-

                                     
Decision Diagnostics Corp. is a nationwide prescription and non-prescription diagnostics and home testing products distributor. We market our GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), our panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), our GenPrecis test strips and meter (for private label sale), and our GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. We are also FDA approved and have complete R&D and manufacturing facilities in South Korea. We made the the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early 2008.

Keith Berman, CEO of DECN commented, "GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology.

https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full

While infectious disease testing and management has not previously been a part of our business model, we seized on this "do good" opportunity because our "Gen" line of products are and have been manufactured since 2016 in what is ground zero for Coronavirus (covid19) in Daegu, Korea. The company will have available samples of the blood of those previously infected available for testing as the company quickly converts its GenUltimate TBG methods and Precise meter, into a precise infectious disease testing device for the screening for Coronavirus."

                                                    



Read Recent Press Releases » 

NEWS
https://www.otcmarkets.com/stock/DECN/news

 

GenViro! 12-Month Forecast

Number of Months	1	2	3	4	5	6	7	8	9	10	11	12	SUM
Year 1	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21
New Facility Customers	0	0	0	0	0	5000	5000	5000	5000	5000	5000	5000
Retained Facilities	0	0	0	0	0	0	5000	10000	15000	20000	25000	30000
Total Facility Customers	0	0	0	0	0	5000	10000	15000	20000	25000	30000	35000	35,000
Kits Consumed	0	0	0	0	0	15,000,000	30,000,000	45,000,000	60,000,000	75,000,000	90,000,000	105,000,000	420,000,000

We are not resting our laurels with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. The Coronavirus kit will be sold for $6.95. Each kit sold will carry enough diagnostic for two tests, a primary test, and a test in reserve in case of human error in administrating the primary test. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.

Mr. Berman concluded, "As you might imagine with a product announcement of such importance, we have been contacted by a number of potential partners for our kit, as well as companies who were not chosen last time to proceed past the proposition stage. The company's first choice for partnering will be a company that made "the cut" last time for our GenUltimate! TBG product. We will discuss partnering potential in a coming release. For the moment, the company is content calling on big box and long term care chains through its existing distributors and agents."

DECN also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leding Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. The company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different manufacture. A GenExpidient! device will be included in every Covid19 kit. Having such a device will lower the incidence of cleaning and disinfecting the GenViro! meter.

ABOUT DECISION DIAGNOSTICS CORP

Decision  

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 11 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.

View source version on accesswire.com:
https://www.accesswire.com/579985/DECN-Provides-First-Looks-At-Its-GenViroTM-Corona-Virus-Screening-Kit-First-Year-Product-Forecast-of-420-Million-Kits-with-Sales-Beginning-Late-3Q-2020


 

SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device
FOR IMMEDIATE RELEASE

2020-327

Washington D.C., Dec. 18, 2020 —
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 2020.

The SEC's complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics' Covid-19 device and progress towards FDA emergency use authorization. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. Further, its advisors had warned that the testing kit they were trying to manufacture would not work as Decision Diagnostics had described. The complaint also alleges that the statements created the misleading impression that the test was soon to be introduced to the market and led to surges in the price and trading volume of Decision Diagnostics' stock.

"During this unprecedented time, when the need for truthful disclosures concerning Covid-19 tests is of vital importance, Decision Diagnostics and its CEO allegedly misled investors by claiming to have made a working test device when all they had was an idea that had not materialized into a product," said Stephanie Avakian, Director of the Division of Enforcement. "With the onset of the global pandemic, we quickly pivoted to identify potential areas of fraud. This case is another example of how the Commission will hold accountable those who exploit the pandemic to harm investors."

"In our complaint, we allege that Decision Diagnostics and Berman repeatedly made baseless representations to the investing public about market-moving events like progress in obtaining FDA approval and having breakthrough technology," said Anita B. Bandy, Associate Director of the Division of Enforcement. "Today's filing is a credit to the dedicated SEC staff, who continued to investigate after the trading suspension and quickly uncovered the alleged fraud."

The complaint, filed in the U.S. District Court for the Southern District of New York, charges Decision Diagnostics and Berman with violating antifraud provisions of the securities laws. The SEC is seeking a court order permanently enjoining both Decision Diagnostics and Berman from directly or indirectly violating those provisions and ordering them to pay civil penalties.

The Department of Justice's Market Integrity and Major Frauds Unit announced today that parallel criminal charges against Berman were also filed in the U.S. District Court for the District of Columbia.

The SEC's investigation, which is continuing, has been conducted by Ernesto Amparo, Carlisle Perkins and Lesley Atkins and supervised by Jeff Leasure and Ms. Bandy with invaluable assistance by Margaret A. Cain of the Office of Market Intelligence and Hane L. Kim of the Microcap Fraud Task Force, both members of the SEC's Coronavirus Steering Committee. The litigation will be handled by James Carlson, David Misler and supervised by Tom Bednar. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.

https://www.sec.gov/news/press-release/2020-327

https://www.sec.gov/litigation/09/complaints/2020/comp-pr2020-327.pdf

 

DECN SECURITY DETAILS

Share Structure

 

Authorized Shares

494,995,000

 

Outstanding Shares

02/14/22 - 380,486,143
11/12/21 - 358,500,583
09/30/21 - 357,780,503
12/17/20 - Berman arrested by FBI
12/11/20 - 349,741,793
11/06/20 - 332,025,278

10/09/20 - 325,752,685

09/11/20 -  313,434,787

08/07/20 - 305,063,608
07/10/20 - 302,663,608
05/15/20 - 267,213,123
04/03/20 - 212,000,000
03/31/20 - 199,792,833

03/06/20 - 159,999,161
12/31/19 - 156,679,161
12/31/18 - 134,551,840
12/31/17 - 110,241,640
12/31/16 - 84,639,908 

 

 

Restricted

07/10/2020 - 5,969,436
10/09/2020 - 9,983,981
12/10/2021 - 18,742,771

 

Unrestricted

12/10/2021 - 339,757,812
02/15/2022 - 361,025,480

 

 

CHARTS
http://schrts.co/efpbEXqx
https://www.tradingview.com/chart/EMwy91xl/
https://www.barchart.com/stocks/quotes/DECN/interactive-chart/fullscreen




https://www.otcmarkets.com/stock/DECN/overview